Epimutations and cancer predisposition: importance and mechanisms - PubMed (original) (raw)

Review

Epimutations and cancer predisposition: importance and mechanisms

Luke B Hesson et al. Curr Opin Genet Dev. 2010 Jun.

Abstract

Germline sequence mutations in tumour suppressor genes can cause cancer predisposition syndromes. More recently, epimutations have also been proposed to cause at least one such syndrome, hereditary non-polyposis colorectal cancer (HNPCC). 'Epigenetic predisposition', is defined as an inherited propensity to an altered epigenetic state in normal tissues that confers a predisposition to disease. Genetic sequence variations acting in cis or trans may contribute to epigenetic variations. Understanding the origin of epimutations will inform cancer risk assessment and will also aid the design and application of new therapies that target the epigenome.

PubMed Disclaimer

Similar articles

• The genetics of hereditary colon cancer.
  Rustgi AK. Rustgi AK. Genes Dev. 2007 Oct 15;21(20):2525-38. doi: 10.1101/gad.1593107. Genes Dev. 2007. PMID: 17938238 Review.
• Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
  Johnson V, Lipton LR, Cummings C, Eftekhar Sadat AT, Izatt L, Hodgson SV, Talbot IC, Thomas HJ, Silver AJ, Tomlinson IP. Johnson V, et al. J Med Genet. 2005 Oct;42(10):756-62. doi: 10.1136/jmg.2005.031245. Epub 2005 Mar 23. J Med Genet. 2005. PMID: 15788729 Free PMC article.
• [Hereditary non polyposis colorectal cancer].
  Dieumegard B. Dieumegard B. Ann Med Interne (Paris). 2001 Sep;152(5):317-21. Ann Med Interne (Paris). 2001. PMID: 11593143 Review. French.
• Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
  Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; Society of Gynecologic Oncologists Education Committee. Lancaster JM, et al. Gynecol Oncol. 2007 Nov;107(2):159-62. doi: 10.1016/j.ygyno.2007.09.031. Gynecol Oncol. 2007. PMID: 17950381

Cited by

• Assessment of tumor suppressor promoter methylation in healthy individuals.
  Poduval DB, Ognedal E, Sichmanova Z, Valen E, Iversen GT, Minsaas L, Lønning PE, Knappskog S. Poduval DB, et al. Clin Epigenetics. 2020 Aug 28;12(1):131. doi: 10.1186/s13148-020-00920-7. Clin Epigenetics. 2020. PMID: 32859265 Free PMC article.
• Intricacies of aetiology in intrafamilial degenerative disease.
  Lowry JL, Ryan ÉB, Esengul YT, Siddique N, Siddique T. Lowry JL, et al. Brain Commun. 2020 Oct 6;2(2):fcaa120. doi: 10.1093/braincomms/fcaa120. eCollection 2020. Brain Commun. 2020. PMID: 33134917 Free PMC article. Review.
• DNA mismatch repair and infertility.
  Mukherjee S, Ridgeway AD, Lamb DJ. Mukherjee S, et al. Curr Opin Urol. 2010 Nov;20(6):525-32. doi: 10.1097/MOU.0b013e32833f1c21. Curr Opin Urol. 2010. PMID: 20852424 Free PMC article. Review.
• MLH1 methylation screening is effective in identifying epimutation carriers.
  Pineda M, Mur P, Iniesta MD, Borràs E, Campos O, Vargas G, Iglesias S, Fernández A, Gruber SB, Lázaro C, Brunet J, Navarro M, Blanco I, Capellá G. Pineda M, et al. Eur J Hum Genet. 2012 Dec;20(12):1256-64. doi: 10.1038/ejhg.2012.136. Epub 2012 Jul 4. Eur J Hum Genet. 2012. PMID: 22763379 Free PMC article.
• Serrated polyposis syndrome: molecular, pathological and clinical aspects.
  Guarinos C, Sánchez-Fortún C, Rodríguez-Soler M, Alenda C, Payá A, Jover R. Guarinos C, et al. World J Gastroenterol. 2012 May 28;18(20):2452-61. doi: 10.3748/wjg.v18.i20.2452. World J Gastroenterol. 2012. PMID: 22654442 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science